Limited Edition Golden Llama is here! Check out how you can get one. 
Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free! Offering SPR-BLI Services - Proteins provided for free!
Here come GMP Grade Cytokines！Free Sample is available！ Here come GMP Grade Cytokines！Free Sample is available！
FACS analysis of Nectin-4 on HEK293/Human Nectin-4 Stable Cell Line.
FACS assay shows that Anti-Nectin-4 antibody can bind to HEK293/Human Nectin-4 Stable Cell Line. HEK293/Human Nectin-4 stable cells was red line, Negative control HEK293 cells was grey line (QC tested).
Mouse Anti-Nectin-4 Antibody (Mouse IgG1) captured on CM5 chip via anti-mouse antibodies surface can bind Cynomolgus Nectin-4, His Tag (Cat. No. NE4-C52H4) with an affinity constant of 824 nM as determined in a SPR assay (Biacore T200) (Routinely tested).
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Enfortumab vedotin | DLE8519RWM; ASG-22ME; AGS-22M6E; ASG-22M6E; ASG-22CE; AGS-22ME; AGS-22C3; AGS-M6; AGS-22C3E | Approved | Agensys Inc | Padcev | United States | Carcinoma, Transitional Cell | Astellas Pharma Us Inc | 2019-12-18 | Kidney Neoplasms; Solid tumours; Carcinoma; Carcinoma, Transitional Cell; Pancreatic Neoplasms; Neoplasms; Prostatic Neoplasms, Castration-Resistant; Urinary Bladder Neoplasms; Urethral Neoplasms; Carcinoma in Situ; Ureteral Neoplasms; Urologic Neoplasms; Carcinoma, Pancreatic Ductal | Details |
| Enfortumab vedotin | DLE8519RWM; ASG-22ME; AGS-22M6E; ASG-22M6E; ASG-22CE; AGS-22ME; AGS-22C3; AGS-M6; AGS-22C3E | Approved | Agensys Inc | Padcev | United States | Carcinoma, Transitional Cell | Astellas Pharma Us Inc | 2019-12-18 | Kidney Neoplasms; Solid tumours; Carcinoma; Carcinoma, Transitional Cell; Pancreatic Neoplasms; Neoplasms; Prostatic Neoplasms, Castration-Resistant; Urinary Bladder Neoplasms; Urethral Neoplasms; Carcinoma in Situ; Ureteral Neoplasms; Urologic Neoplasms; Carcinoma, Pancreatic Ductal | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| 9MW2821 | 9MW2821; 9MW-2821; 9-MW2821; 9-MW-2821 | Phase 3 Clinical | Mabwell (Shanghai) Bioscience Co Ltd | Solid tumours; Carcinoma, Transitional Cell | Details |
| BT-8009 | BT-8009 | Phase 3 Clinical | Bicycle Tx Ltd | Ovarian Neoplasms; Solid tumours; Triple Negative Breast Neoplasms; Carcinoma, Transitional Cell; Urinary Bladder Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| BT-7480 | BT-7480 | Phase 2 Clinical | Bicycle Therapeutics | Solid tumours; Neoplasms | Details |
| SYS-6002 | SYS-6002; SYS6002; CRB-701 | Phase 2 Clinical | Jushi Biopharmaceutical Co Ltd, CSPC Pharmaceutical Group Ltd | Solid tumours | Details |
| Nectin4/FAP-targeted CAR-T cell therapy (The Sixth Affiliated Hospital of Wenzhou Medical University) | Phase 1 Clinical | Wenzhou Medical University, The Sixth Affiliated Hospital Of Wenzhou Medical University | Solid tumours | Details | |
| ETx-22 | ETx-22; LY4101174 | Phase 1 Clinical | Emergence Therapeutics AG | Ovarian Neoplasms; Solid tumours; Pelvic Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Pancreatic Neoplasms; Triple Negative Breast Neoplasms; Urinary Bladder Neoplasms; Prostatic Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Neoplasm Metastasis | Details |
| ADRX-0706 | ADRX-0706 | Phase 1 Clinical | Adcentrx Therapeutics Inc | Solid tumours; Neoplasms | Details |
| SKB-410 | SKB410; SKB-410 | Phase 1 Clinical | Sichuan Kelun-Biotech Biopharmaceutical Co Ltd | Solid tumours | Details |
| BAT-8007 | BAT-8007 | Phase 1 Clinical | Bio-Thera Solutions Ltd | Solid tumours | Details |
| SHR-A2102 | SHR-A2102 | Phase 1 Clinical | Shanghai Hengrui Pharmaceutical Co Ltd | Solid tumours | Details |
| 9MW2821 | 9MW2821; 9MW-2821; 9-MW2821; 9-MW-2821 | Phase 3 Clinical | Mabwell (Shanghai) Bioscience Co Ltd | Solid tumours; Carcinoma, Transitional Cell | Details |
| BT-8009 | BT-8009 | Phase 3 Clinical | Bicycle Tx Ltd | Ovarian Neoplasms; Solid tumours; Triple Negative Breast Neoplasms; Carcinoma, Transitional Cell; Urinary Bladder Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
| BT-7480 | BT-7480 | Phase 2 Clinical | Bicycle Therapeutics | Solid tumours; Neoplasms | Details |
| SYS-6002 | SYS-6002; SYS6002; CRB-701 | Phase 2 Clinical | Jushi Biopharmaceutical Co Ltd, CSPC Pharmaceutical Group Ltd | Solid tumours | Details |
| Nectin4/FAP-targeted CAR-T cell therapy (The Sixth Affiliated Hospital of Wenzhou Medical University) | Phase 1 Clinical | Wenzhou Medical University, The Sixth Affiliated Hospital Of Wenzhou Medical University | Solid tumours | Details | |
| ETx-22 | ETx-22; LY4101174 | Phase 1 Clinical | Emergence Therapeutics AG | Ovarian Neoplasms; Solid tumours; Pelvic Neoplasms; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; Pancreatic Neoplasms; Triple Negative Breast Neoplasms; Urinary Bladder Neoplasms; Prostatic Neoplasms; Lung Neoplasms; Carcinoma, Non-Small-Cell Lung; Uterine Cervical Neoplasms; Neoplasm Metastasis | Details |
| ADRX-0706 | ADRX-0706 | Phase 1 Clinical | Adcentrx Therapeutics Inc | Solid tumours; Neoplasms | Details |
| SKB-410 | SKB410; SKB-410 | Phase 1 Clinical | Sichuan Kelun-Biotech Biopharmaceutical Co Ltd | Solid tumours | Details |
| BAT-8007 | BAT-8007 | Phase 1 Clinical | Bio-Thera Solutions Ltd | Solid tumours | Details |
| SHR-A2102 | SHR-A2102 | Phase 1 Clinical | Shanghai Hengrui Pharmaceutical Co Ltd | Solid tumours | Details |
This web search service is supported by Google Inc.
A-Z
